Monitor all patients for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of therapy or at times of increases or decreases in dose. Monitor all patients with hepatic or renal impairment for possible adverse reactions that could indicate high drug and/or metabolite levels. Monitor BP in patients receiving a combination of bupropion and nicotine replacement. Frequently assess patient for response to treatment. Periodically review therapy to determine if therapy needs to be continued without change or if a dose change (eg, increase, decrease, discontinuation) is indicated.